Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 5/20 | 0.36 |
| ▸ | DRD4 | P21917 | 2/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.35 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.35 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7596316 | 0.80 | CHRNB2 (0.51) | HSD17B10CHRNA7KMT2AMEN1CHRNB2 | |
| SCHEMBL7692431 | 0.78 | CHRNA7 (0.52) | CHRNA7ALDH1A1MAPTRXFP1RAB9A | |
| SCHEMBL7126424 | 0.77 | HDAC1 (0.46) | CHRNA7MAPTRXFP1CHRNB2CHRNA4 | |
| SCHEMBL7129660 | 0.76 | CHRNA7 (0.38) | CHRNA7ALDH1A1CHRM3KMT2AMEN1 | |
| SCHEMBL7062241 | 0.76 | CHRNB2 (0.50) | CHRNA7ALDH1A1MAPTKMT2AMEN1 | |
| SCHEMBL7118213 | 0.76 | CHRNA7 (0.42) | CHRNA7ALDH1A1CHRM3RXFP1KMT2A | |
| SCHEMBL7125795 | 0.76 | USP30 (0.43) | CHRNA7ALDH1A1MAPTKMT2AMEN1 | |
| SCHEMBL7654015 | 0.75 | FPR2 (0.38) | HSD17B10ALDH1A1 | |
| SCHEMBL7220020 | 0.74 | HDAC1 (0.49) | CHRNA7CHRNB2CHRNA4 | |
| SCHEMBL5955656 | 0.73 | CHRNA7 (0.39) | CHRNA7ALDH1A1MAPTRXFP1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020042429-A1 | Quinuclidine-substituted heteroaryl moieties for treatment of disease | PHARMACIA & UPJOHN COMPANY | 2002-04-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020042429-A1 | Quinuclidine-substituted heteroaryl moieties for treatment of disease | PARK7, CYP3A7, UGT2B7 | HSD17B10 346/4885CHRNA7 28/4885ALDH1A1 267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.